Department of Cardiology, Heart Center Leipzig - University Hospital, Leipzig, Germany.
Department of Cardiac Surgery, Heart Center Leipzig - University Hospital, Leipzig, Germany.
JACC Cardiovasc Interv. 2018 Jun 25;11(12):1142-1151. doi: 10.1016/j.jcin.2018.04.010.
The present study aimed to test the clinical benefit of combined transcatheter mitral plus tricuspid valve edge-to-edge repair (TMTVR) as compared with transcatheter mitral valve edge-to-edge repair (TMVR) alone in patients with both significant mitral (MR) and tricuspid regurgitation (TR) at high surgical risk.
A growing number of patients with severe MR at increased surgical risk are treated by transcatheter techniques. Evidence suggests that residual TR remains a predictor of adverse outcome in these patients.
Sixty-one patients (mean age 79.5 ± 8.4 years, EuroSCORE II 8.6 ± 5.9%) underwent TMTVR (n = 27) or TMVR (n = 34). Echocardiographic and cardiac magnetic resonance imaging was performed before and after the procedure.
Reduction of MR was similar in patients undergoing TMTVR and TMVR. Effective regurgitant orifice area of TR was reduced from 0.51 to 0.29 cm in patients with TMTVR (p < 0.01), but remained unchanged after TMVR. On cardiac magnetic resonance imaging, only patients in the TMTVR group exhibited improved effective right and left ventricular stroke volume, and increased cardiac index (2.1 vs. 2.5 l/min/m; p < 0.01). TMTVR led to superior improvement in New York Heart Association functional class, NT-proBNP levels, and 6-min walking distance as compared with TMVR. After up to 18 months of follow-up, patients with TMTVR experienced fewer hospitalizations for heart failure when compared with patients with TMVR (p = 0.02), whereas rates of death were comparable between both groups of patients.
TMTVR appears superior to TMVR in terms of cardiac output and functional improvement early after the intervention, and improves clinical outcome up to 18 months of follow-up.
本研究旨在比较经导管二尖瓣瓣环成形术(TMVR)联合三尖瓣瓣环成形术(TMTVR)与单纯 TMVR 治疗高手术风险的二尖瓣(MR)和三尖瓣反流(TR)均显著的患者的临床获益。
越来越多的高手术风险的严重 MR 患者接受经导管技术治疗。有证据表明,残余 TR 仍然是这些患者不良结局的预测因素。
61 例患者(平均年龄 79.5±8.4 岁,EuroSCORE II 8.6±5.9%)接受 TMTVR(n=27)或 TMVR(n=34)治疗。术前和术后均行超声心动图和心脏磁共振成像检查。
TMTVR 和 TMVR 患者的 MR 减少程度相似。TR 的有效反流口面积从 TMTVR 患者的 0.51cm²降至 0.29cm²(p<0.01),而 TMVR 患者的 TR 有效反流口面积则无变化。心脏磁共振成像仅显示 TMTVR 组患者的右心室和左心室射血分数增加,心指数增加(2.1 比 2.5 l/min/m;p<0.01)。与 TMVR 相比,TMTVR 可改善纽约心脏协会心功能分级、NT-proBNP 水平和 6 分钟步行距离。在 18 个月的随访期间,与 TMVR 相比,TMTVR 患者因心力衰竭住院的次数较少(p=0.02),而两组患者的死亡率相当。
TMTVR 在术后早期改善心输出量和功能方面优于 TMVR,并在 18 个月的随访期间改善临床结局。